Brainstorm Cell Therapeutics Inc. has announced that it has entered into a securities purchase agreement with Vanquish Funding Group Inc., under which Vanquish provided funding of $155,000 to the company in exchange for a promissory note with a principal amount of $182,400. The note, which bears interest at 12% and matures on August 30, 2026, is convertible into shares of Brainstorm's common stock at a 35% discount to the lowest trading price in the 10 days prior to conversion, subject to a 4.99% beneficial ownership cap, in the event of a default. The transaction was conducted as a private placement and the conversion shares, when issued, will be exempt from registration under Section 4(a)(2) of the Securities Act. The agreement also provides for the potential of up to $2 million in additional financing from Vanquish over the next twelve months.